Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Inventory (2017 - 2025)

Historic Change in Inventory for Neurocrine Biosciences (NBIX) over the last 8 years, with Q4 2025 value amounting to $3.4 million.

  • Neurocrine Biosciences' Change in Inventory fell 7068.97% to $3.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $15.3 million, marking a year-over-year decrease of 1989.53%. This contributed to the annual value of $15.3 million for FY2025, which is 1989.53% down from last year.
  • Neurocrine Biosciences' Change in Inventory amounted to $3.4 million in Q4 2025, which was down 7068.97% from $12.3 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Change in Inventory ranged from a high of $12.3 million in Q3 2025 and a low of -$2.9 million during Q3 2023
  • Moreover, its 4-year median value for Change in Inventory was $1.7 million (2025), whereas its average is $2.4 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Change in Inventory surged by 118888.89% in 2024, and later plummeted by 13962.26% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Change in Inventory stood at $2.1 million in 2021, then plummeted by 57.14% to $900000.0 in 2023, then surged by 1188.89% to $11.6 million in 2024, then tumbled by 70.69% to $3.4 million in 2025.
  • Its Change in Inventory was $3.4 million in Q4 2025, compared to $12.3 million in Q3 2025 and -$2.1 million in Q2 2025.